Fused or hybrid protein comprising viral antigen and lymphokine
CA 2020668 C · Owner: Hinuma, Shuji · Inventors: Hinuma, Shuji; Fujisawa, Yukio; Mayumi, Aki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are (1) a fused protein obtained by combining an antigen used for vaccine and a lymphokine by the application of gene engineering, (2) a recombinant DNA containing a nucleotide sequence coding for the above fused protein, (3) a transformant bearing the above recombinant DNA, (4) a method for producing the fused protein which comprises cultivating the above transformant producing and, accumulating the above fused protein in a culture and, collecting the fused protein, and (5) a hybrid protein obtained by chemically combining an antigen used for vaccine with a lymphokine. The resulting fused and hybrid proteins have strong immunogenicity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 6, 1990 and granted October 2, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 6, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 6, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.